Home > D. Systemic pathology > Toxics and drugs > Nutlin-3A
Nutlin-3A
Friday 29 February 2008
The MDM2-antagonist Nutlin 3A can efficiently induce apoptosis in osteosarcoma cell lines with amplified MDM2. Nutlin-based therapy could be even more important in more common sarcoma types where this aberration is frequent as well- and de-differentiated liposarcomas. Nutlin represents a promising new therapeutic principle for the treatment of an increasing group of sarcomas.
References
Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer. 2007 Jul 1;121(1):199-205. PMID: 17354236
